NCT06396403Completed
The Role of Red Cell Characteristics, Angiogenesis, Viscosity and Oxygenation in the Pathophysiology of Sickle Cell Related Retinopathy
Source: ClinicalTrials.gov · Last updated 15 Nov 2024
Brief summary (registry, in English)
Objective: to gain insight in the pathogenesis, to identify biomarkers to recognize patients at risk for proliferative SCR and to investigate its associations with clinical and laboratory characteristics. Endpoints: The investigators will determine the difference in the above named parameters between patients with and without PSCR Study design: This case control study will include adult sickle cell disease patients with the HbSS or HbSC genotype. For both genotypes, 20 patients without sickle cell retinopathy (SCR) and 20 patients with PSCR will be included, resulting in a total of 80 patients. Venous blood samples and retinal imaging scans will be collected for each included patient.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 68 (actual)
- First submitted
- 24 Apr 2024
- Start date
- 13 Jun 2023
- Primary completion date
- 17 Jun 2024
- Lead sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Diseases
- Sickle cell disease
- NCT number
- NCT06396403
What you commit to
- Study type: Observational
- Participants enrolled: 68
- From 13 Jun 2023 to the primary completion date, 17 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- Age below 18 years
Other
- Genotype other than HbSC or HbSS
- No recent ophthalmologic examination and no intention to visit the outpatient clinic for ophthalmic and hematologic examination
- Participation in trials with either crizanlizumab, voxelotor or mitapivat.
Who the study is looking for
- Minimum age of 18 years
- HbSC or HbSS genotype
- Recent ophthalmologic examination (up to 2 years prior) or (willingness to attend) upcoming examination
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Amsterdam UMC Coordinator of this site? Confirm its status | Amsterdam | Netherlands | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.